PharmaCyte Biotech Inc (PMCB)

[aramire]

So I could not wrap my mind around how CIB could go from going head to head against "Th Gold Standard" (GS) to being a secondary "consolidation" treatment that is now going to be matched up against a different drug all together. That is until I read this article about news coming from the 2015 GI Symposium.

What I gather, and feel free to correct me, is that Celgene reported at the symposium that it has new and better results by simply administering the GS biweekly as opposed to weekly. The numbers used by PMCB on their website reference the Mean Overall Survival (OS) of 8.5 months for the GS, but that was based on a weekly dosage rate. The new OS is 11.1 months. Which actually beats CIB by 0.1 months. The 1 year survival rates were already pretty much even.

So then you move to side effects and pain levels and the article addresses that as well basically stating that by administering biweekly that the pertinent negatives decrease as well as logic would assume. So I believe now I see why they are no longer going head to head vs The GS anymore. The audio interview does mention Progression Free Survival (PFS) as an end point to the study and the biweekly treatment of the GS is 4.8 months. According to the interview the PFS for CIB will be measured at the 6 and 12 month mark.

For me CIB is counterproductive if you are having to inject it everywhere in the abdominal cavity so a prerequisite for it to be useful is that the cancer cannot have mestasticized by the time CIB is considered for use. What I found interesting before reading this article was that PMCB was conceding now that a prerequisite for the upcoming trial was that eligible patients had to have localized inoperable cancer AND hadb een taking the the GS for 4-6 months. I found that astonishing that PMCB was basically admitting that the GS was and still is the primary drug to treat pancreatic cancer, if not you would not need these patients to have taken the GS previously.

For my part, I hold a considerable position in PMCB, based on my finances. So this is not a bashing post. For me it is more talking aloud and seeing if others see this the same. I actually looked forward to seeing CIB go head to head with the GS but I guess that will no longer happen. Oh well, now on to diabetes I guess.

http://www.curetoday.com/articles/adjusted-regimen-of-abraxane-and-gemzar-less-toxic-in-pancreatic-cancer